[1]Benet L Z, Galeazzi R L. 1979. Noncompartmental determination of the steady-state volume of distribution. Journal of Pharmaceutical Sciences, 68, 1071-1074. [2]Canga A G , Prieto A M S, Liebana M J D, Martinez N F, Vega M S, Vieitez J J G. 2009. The pharmacokinetics and metabolism of ivermectin in domestic animal species. The Veterinary Journal, 179, 25-37. [3]Chen Q, Tang S, Jin X, Zou J, Chen K, Zhang T, Xiao X. 2009. Investigation of the genotoxicity of quinocetone, carbadox and olaquindox in vitro using Vero cells. Food and Chemical Toxicology, 47, 328-334. [4]Chen Z L. 2002. Veterinary Pharmacology. 2nd ed. China Agrlculture Press, Beijing. p. 240. (in Chinese) Cutler D J. 1978. Theory of the absorption time, an adjunct to conventional bioavailability studies. Journal of Pharmacy and Pharmacology, 30, 476-478. [5]Du Z M, Yang L Z, Li S Z, Wang H Z, Bie C Q, Liu Y Q. 2008. Diagnosis and treatment of mequindox posining in chickens. Journal of Animal Science and Veterinary Medicine, 27, 118, 120. (in Chinese) Gibaldi M, Perrier D, 1982. Pharmacokinetics. 2nd ed. Marrcel Dekker, New York. pp. 409-417. [6]Huang X J, Ihsan A, Wang X, Dai M H, Wang Y L, Su S J, Xue X J, Yuan Z H. 2009. Long-term dose-dependent response of Mequindox on aldosterone, corticosterone and five steroidogenic enzyme mRNAs in the adrenal of male rats. Toxicology Letters, 191, 167-173. [7]Huang X J, Wang X, Ihsan A, Liu Q, Xue X J, Su S J, Yang C H, Zhou W, Yuan Z H. 2010. Interactions of NADPH oxidase, renin-angiotensin-aldosterone system and reactive oxygen species in mequindox-mediated aldosterone secretion in Wistar rats. Toxicology Letters, 198, 112-118. [8]Huang Y Q, Li Y Q, Yang Y J, Miao X L, Xie Y, Bai D Y, Lu C W, Sun L, Ma B Z. 2008. Studies on the pharmacokinetics of Mequindox in sheep. Journal of Northwest A&F University (Natural Science Edition), 36, 77-81. (in Chinese) [9]Kimura T, Higaki K. 2002. Gastrointestinal transit and drug absorption. Biological and Pharmaceutical Bulletin, 25, 149- 164. Knauf H, Mutschler E. 1995. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. Journal of Cardiovascular Pharmacology, 26, 394-400. [10]Lappin G, Rowland M, Garner R C. 2006. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opinion on Drug Metabolism & Toxicology, 2, 419-427. [11]Liu Y C, Si H B, He L M, Ding H Z, Huang X H, Chen J X, Chen Z L, Zeng Z L. 2010. Identification of mequindox and Its metabolites by high performance liquid chromatography combined with ion trap-time of flight-mass spectrometry. Chinese Journal of Analytical Chemistry, 10, 82-86. (in Chinese) [12]Liu Z Y, Huang L L, Chen D M, YUAN Z H. 2010. Metabolism of mequindox in liver microsomes of rats, chicken and pigs. Rapid Communications in Mass Spectrometry, 24, 909-918. [13]Lu C W, Li Y Q, Guan Y J, Zhang Y B, Bai D Y, Miao X L, Xiong Y J 2008. Pharmacokinetics of maquindox in rabbits with experimental hepatic injury. Journal of Northwest A&F University (Natural Science Edition), 36, 29-34. (in Chinese) [14]Mirfazaelian A, Mahmoudian M. 2006. A simple pharmacokinetics subroutine for modeling double peak phenomenon. Biopharmaceutics & Drug Disposition, 27, 119-124. [15]Ni J B, Zhang J C, Cheng S P. 2007. Diagnosis and treatment of mequindox posining in pigs. Chinese Journal of Animal Husbandry and Veterinary Medicine, 8, 66. (in Chinese) [16]Nie M Q, Guo X Q. 2009. Diagnosis and treatment of mequindox posining in chickens. Technical Advisor for Animal Husbandry, 3, 58. (in Chinese) [17]Nielsen P, Gyrd-Hansen N. 1996. Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. Journal of Veterinary Pharmacology and Therapeutics, 19, 305-311. [18]Plusquellec Y, Campistron G, Staveris S, Barre J, Jung L, Tillement J P, Houin G. 1987. A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. Journal of Pharmacokinetics and Biopharmaceutics, 15, 225-239. [19]Polli J E, Bigora S, Piscitelli D A, Straughn A B, Young D. 1996. ‘Pavlovian’ food effect on the enterohepatic recirculation of piroxicam. Biopharmaceutics & Drug Disposition, 17, 635- 641. [20]Riley S A, Sutcliffe F, Kim M, Kapas M, Rowland M, Turnberg L A. 1992. The influence of gastrointestinal transit on drug absorption in healthy volunteers. British Journal of Clinical Pharmacology, 34, 32-39. [21]Rolan P, Molnar V. 2006. Clinical pharmacokinetics. In: Griffin J P, O’Grady J, Wells F O, eds., The Textbook of Pharmaceutical Medicine. 5th ed. Blackwell Pub. Malden, MA. pp. 176-197. [22]Schulze J D R, Waddington W A, Ell P J, Parsons G E, Coffin M D, Basit A W. 2003. Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption. Pharmaceutical Research, 20, 1984-1988. [23]Spilsbury M L A. 2010. Clinical reports of carbadox toxicity in Mexican swine farms. Research Journal of Biological Sciences, 5, 9-12. [24]Varum F J O, Merchant H A, Basit A W. 2010. Oral modifiedrelease formulations in motion: The relationship between gastrointestinal transit and drug absorption. International Journal of Pharmaceutics, 395, 26-36. [25]Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, Mrazek C, Wegner D, Nagel S, Siegmund W. 2005. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharmaceutical Research, 22, 728-735. [26]Wilding I R, Davis S S, Hardy J G, Robertson C S, John V A, Powell M L, Leal M, Lloyd P, Walker S M. 1991. Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. British Journal of Clinical Pharmacology, 32, 573-579. [27]Yamaoka K, Nakagawa T, Uno T. 1978. Statistical moments in pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics, 6, 547-558. [28]Yin O Q, Tomlinson B, Chow A H, Chow M S. 2003. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine. Clinical Pharmacokinetics, 42, 179-192. [29]Zhao R, Xia W, Wang Y. 1982. Antibacterial activity and toxicity of “MAQO” and “MCEQO”. Journal of Traditional Chinese Veterinary Medicine, 1, 52-54. (in Chinese) [30]Zhou H W, Shen J Q, Lu M, Liang W Q, Lin W, Zhao W H. 1992. Pharmacokinetic analysis of enterohepatic circulation of piroxicam in rabbits. Acta Pharmacologica Sinica, 13, 180- 182. (in Chinese) [31]Zou J J, Chen Q, Tang S S, Jin X, Chen K P, Zhang T, Xiao X L. 2009. Olaquindox-induced genotoxicity and oxidative DNA damage in human hepatoma G2 (HepG2) cells. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 676, 27-33. |